Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (261-270 of 459) with videos related to

Pageof 46
Sort By:
Expert Opinion on Investigational Drugs|March 10, 2015
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancerMatteo Santoni, Francesco Massari, Marzia Del Re, et al.
Immunotherapy|April 28, 2021
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysisAlessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Communications Medicine|May 27, 2026
Microplastics as both a driver of genitourinary cancers and a deliverer of treatmentsKannan Sridharan, Brigida Anna Maiorano, Farah Rehan, et al.
Journal of Clinical Medicine|October 16, 2024
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future PerspectivesSamuele Compagno, Chiara Casadio, Linda Galvani, et al.
Expert Review of Molecular Diagnostics|October 24, 2019
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancerVeronica Mollica, Vincenzo Di Nunno, Matteo Santoni, et al.
Expert Review of Anticancer Therapy|March 24, 2016
Prostate cancer: from Gleason scoring to prognostic grade groupingRodolfo Montironi, Matteo Santoni, Roberta Mazzucchelli, et al.
Oncotarget|December 7, 2017
The TRPV1 ion channel regulates thymocyte differentiation by modulating autophagy and proteasome activityConsuelo Amantini, Valerio Farfariello, Claudio Cardinali, et al.
Clinical Drug Investigation|April 3, 2019
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the RevolutionVeronica Mollica, Vincenzo Di Nunno, Lidia Gatto, et al.
Future Oncology (London, England)|August 25, 2018
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancerVincenzo Di Nunno, Alessia Cimadamore, Matteo Santoni, et al.
Cancer Medicine|January 2, 2024
Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetateOndřej Fiala, Petr Hošek, Hana Korunková, et al.
Pageof 46

Showing results (261-270 of 459) with videos related to

Sort By:
Pageof 46
Expert Opinion on Investigational Drugs|March 10, 2015
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancerMatteo Santoni, Francesco Massari, Marzia Del Re, et al.
Immunotherapy|April 28, 2021
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysisAlessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Communications Medicine|May 27, 2026
Microplastics as both a driver of genitourinary cancers and a deliverer of treatmentsKannan Sridharan, Brigida Anna Maiorano, Farah Rehan, et al.
Journal of Clinical Medicine|October 16, 2024
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future PerspectivesSamuele Compagno, Chiara Casadio, Linda Galvani, et al.
Expert Review of Molecular Diagnostics|October 24, 2019
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancerVeronica Mollica, Vincenzo Di Nunno, Matteo Santoni, et al.
Expert Review of Anticancer Therapy|March 24, 2016
Prostate cancer: from Gleason scoring to prognostic grade groupingRodolfo Montironi, Matteo Santoni, Roberta Mazzucchelli, et al.
Oncotarget|December 7, 2017
The TRPV1 ion channel regulates thymocyte differentiation by modulating autophagy and proteasome activityConsuelo Amantini, Valerio Farfariello, Claudio Cardinali, et al.
Clinical Drug Investigation|April 3, 2019
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the RevolutionVeronica Mollica, Vincenzo Di Nunno, Lidia Gatto, et al.
Future Oncology (London, England)|August 25, 2018
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancerVincenzo Di Nunno, Alessia Cimadamore, Matteo Santoni, et al.
Cancer Medicine|January 2, 2024
Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetateOndřej Fiala, Petr Hošek, Hana Korunková, et al.
Pageof 46